NAMS MSCP Certification Exam Practice Test Bank
Verified Questions, Answers, & Rationales (2026 Update)
Section 1: Physiology & Diagnosis of Menopause
Q1: According to the STRAW + 10 criteria, a woman is officially in the early stage
of the menopause transition (Stage -1) if she experiences:
A) A complete cessation of menses for 12 months.
B) A persistent difference of 7 days or more in the length of consecutive menstrual
cycles.
C) An interval of amenorrhea of 60 days or more.
D) A serum FSH level > 25 IU/L on two separate occasions.
CORRECT ANSWER>: B) A persistent difference of 7 days or more in the length of
consecutive menstrual cycles.
Rationale: STRAW + 10 defines the early menopause transition (Stage -1) by
increased variability in cycle length, defined as a persistent difference of ≥7 days in
the length of consecutive cycles. Late transition (Stage -2) is characterized by
intervals of amenorrhea of ≥60 days. Stage +1 (postmenopause) is 12 months of
amenorrhea.
Q2: Which of the following laboratory tests is considered the most specific marker
of ovarian reserve and shows a steep decline approximately 5 years prior to the
final menstrual period?
A) Serum FSH
B) Serum Estradiol
C) Anti-Müllerian Hormone (AMH)
D) Serum Inhibin B
,CORRECT ANSWER>: C) Anti-Müllerian Hormone (AMH)
Rationale: AMH is produced by granulosa cells of small follicles and is the most
sensitive marker of ovarian reserve. It declines steadily with age and becomes
undetectable in the late menopause transition. FSH and estradiol fluctuate
significantly and are less reliable for staging menopause.
Q3: A 48-year-old woman presents with irregular menses, hot flashes, and new-
onset mood lability. Her TSH is normal. Which physiological mechanism is
primarily responsible for her vasomotor symptoms?
A) Absolute estrogen deficiency
B) Rapid fluctuations in estrogen levels affecting the hypothalamic
thermoregulatory zone
C) Progesterone excess causing prostaglandin release
D) Primary adrenal insufficiency
CORRECT ANSWER>: B) Rapid fluctuations in estrogen levels affecting the
hypothalamic thermoregulatory zone
Rationale: Vasomotor symptoms (VMS) are not solely caused by low estrogen
(which is why young girls and women with primary amenorrhea don't get hot
flashes). They are caused by the fluctuation of estrogen, which narrows the
thermoneutral zone in the hypothalamus, making the body hyper-responsive to
minor temperature changes.
Section 2: Vasomotor Symptoms (VMS) & Hormone Therapy (HT)
Q4: According to the Menopause Society Position Statement, for a woman < 60
years old or within 10 years of menopause onset who has no contraindications,
the benefit-risk ratio of systemic hormone therapy is:
A) Favorable for the treatment of vasomotor symptoms and bone loss.
, B) Unfavorable due to an unacceptable risk of breast cancer.
C) Favorable only if she has had a hysterectomy.
D) Unfavorable due to a high risk of venous thromboembolism (VTE).
CORRECT ANSWER>: A) Favorable for the treatment of vasomotor symptoms and
bone loss.
Rationale: The "timing hypothesis" states that for women < 60 or < 10 years from
menopause onset, the benefits of HT (relief of VMS, prevention of bone loss,
reduced fracture risk) outweigh the risks. The risk of VTE, stroke, and breast
cancer is low in this demographic.
Q5: Which of the following routes of estrogen administration is associated with
the lowest risk of venous thromboembolism (VTE) and stroke?
A) Oral conjugated equine estrogens (CEE)
B) Oral estradiol
C) Transdermal estradiol (patch, gel, or spray)
D) Sublingual estradiol
CORRECT ANSWER>: C) Transdermal estradiol (patch, gel, or spray)
Rationale: Oral estrogen undergoes "first-pass" metabolism in the liver, which
increases clotting factors and triglycerides, raising VTE and stroke risk.
Transdermal estrogen bypasses the liver, avoiding first-pass effects, and
observational data strongly suggests it carries a significantly lower risk of VTE and
stroke compared to oral routes.
Q6: A 52-year-old woman with an intact uterus is prescribed transdermal
estradiol. Which progestogen regimen provides the most endometrial protection
while mimicking physiological cycles?
Verified Questions, Answers, & Rationales (2026 Update)
Section 1: Physiology & Diagnosis of Menopause
Q1: According to the STRAW + 10 criteria, a woman is officially in the early stage
of the menopause transition (Stage -1) if she experiences:
A) A complete cessation of menses for 12 months.
B) A persistent difference of 7 days or more in the length of consecutive menstrual
cycles.
C) An interval of amenorrhea of 60 days or more.
D) A serum FSH level > 25 IU/L on two separate occasions.
CORRECT ANSWER>: B) A persistent difference of 7 days or more in the length of
consecutive menstrual cycles.
Rationale: STRAW + 10 defines the early menopause transition (Stage -1) by
increased variability in cycle length, defined as a persistent difference of ≥7 days in
the length of consecutive cycles. Late transition (Stage -2) is characterized by
intervals of amenorrhea of ≥60 days. Stage +1 (postmenopause) is 12 months of
amenorrhea.
Q2: Which of the following laboratory tests is considered the most specific marker
of ovarian reserve and shows a steep decline approximately 5 years prior to the
final menstrual period?
A) Serum FSH
B) Serum Estradiol
C) Anti-Müllerian Hormone (AMH)
D) Serum Inhibin B
,CORRECT ANSWER>: C) Anti-Müllerian Hormone (AMH)
Rationale: AMH is produced by granulosa cells of small follicles and is the most
sensitive marker of ovarian reserve. It declines steadily with age and becomes
undetectable in the late menopause transition. FSH and estradiol fluctuate
significantly and are less reliable for staging menopause.
Q3: A 48-year-old woman presents with irregular menses, hot flashes, and new-
onset mood lability. Her TSH is normal. Which physiological mechanism is
primarily responsible for her vasomotor symptoms?
A) Absolute estrogen deficiency
B) Rapid fluctuations in estrogen levels affecting the hypothalamic
thermoregulatory zone
C) Progesterone excess causing prostaglandin release
D) Primary adrenal insufficiency
CORRECT ANSWER>: B) Rapid fluctuations in estrogen levels affecting the
hypothalamic thermoregulatory zone
Rationale: Vasomotor symptoms (VMS) are not solely caused by low estrogen
(which is why young girls and women with primary amenorrhea don't get hot
flashes). They are caused by the fluctuation of estrogen, which narrows the
thermoneutral zone in the hypothalamus, making the body hyper-responsive to
minor temperature changes.
Section 2: Vasomotor Symptoms (VMS) & Hormone Therapy (HT)
Q4: According to the Menopause Society Position Statement, for a woman < 60
years old or within 10 years of menopause onset who has no contraindications,
the benefit-risk ratio of systemic hormone therapy is:
A) Favorable for the treatment of vasomotor symptoms and bone loss.
, B) Unfavorable due to an unacceptable risk of breast cancer.
C) Favorable only if she has had a hysterectomy.
D) Unfavorable due to a high risk of venous thromboembolism (VTE).
CORRECT ANSWER>: A) Favorable for the treatment of vasomotor symptoms and
bone loss.
Rationale: The "timing hypothesis" states that for women < 60 or < 10 years from
menopause onset, the benefits of HT (relief of VMS, prevention of bone loss,
reduced fracture risk) outweigh the risks. The risk of VTE, stroke, and breast
cancer is low in this demographic.
Q5: Which of the following routes of estrogen administration is associated with
the lowest risk of venous thromboembolism (VTE) and stroke?
A) Oral conjugated equine estrogens (CEE)
B) Oral estradiol
C) Transdermal estradiol (patch, gel, or spray)
D) Sublingual estradiol
CORRECT ANSWER>: C) Transdermal estradiol (patch, gel, or spray)
Rationale: Oral estrogen undergoes "first-pass" metabolism in the liver, which
increases clotting factors and triglycerides, raising VTE and stroke risk.
Transdermal estrogen bypasses the liver, avoiding first-pass effects, and
observational data strongly suggests it carries a significantly lower risk of VTE and
stroke compared to oral routes.
Q6: A 52-year-old woman with an intact uterus is prescribed transdermal
estradiol. Which progestogen regimen provides the most endometrial protection
while mimicking physiological cycles?
